235 results on '"Bermejo A"'
Search Results
2. Reply
3. Early Azathioprine Therapy Is No More Effective Than Placebo for Newly Diagnosed Crohn's Disease
4. Optimized Nonbismuth Quadruple Therapies Cure Most Patients With Helicobacter pylori Infection in Populations With High Rates of Antibiotic Resistance
5. Mo1534: ASSOCIATION OF GOLIMUMAB TROUGH CONCENTRATIONS DURING MAINTENANCE WITH ENDOSCOPIC AND HISTOLOGIC REMISSION IN PATIENTS WITH ULCERATIVE COLITIS.
6. Mo1534: ASSOCIATION OF GOLIMUMAB TROUGH CONCENTRATIONS DURING MAINTENANCE WITH ENDOSCOPIC AND HISTOLOGIC REMISSION IN PATIENTS WITH ULCERATIVE COLITIS
7. 1264 LARGE MULTI-COHORT STUDY SHOWS ACCURATE DETECTION OF EARLY-STAGE COLORECTAL CANCER AND ADVANCED ADENOMA PATIENTS USING CELL-FREE DNA METHYLATION AND FRAGMENTATION SIGNALS
8. Cancer Characteristics in Swedish Families Fulfilling Criteria for Hereditary Nonpolyposis Colorectal Cancer
9. Serial Tuberculin Skin Test Improves the Detection of Latent Tuberculosis Infection in Inflammatory Bowel Disease Patients
10. Su1149 Two-Week, High-Dose Proton Pump Inhibitor, Moxifloxacin Triple H. pylori Therapy After Failure of Standard Triple or Non-Bismuth Quadruple Treatments
11. Su1130 Second-Line Rescue Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection: Time Trends in a Spanish Multicenter Study of 1,500 Patients
12. Tu1996 Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicenter Study
13. Serial Tuberculin Skin Test Improves the Detection of Latent Tuberculosis Infection in Inflammatory Bowel Disease Patients
14. Su1130 Second-Line Rescue Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection: Time Trends in a Spanish Multicenter Study of 1,500 Patients
15. Su1149 Two-Week, High-Dose Proton Pump Inhibitor, Moxifloxacin Triple H. pylori Therapy After Failure of Standard Triple or Non-Bismuth Quadruple Treatments
16. Tu1996 Prevalence and Factors Associated With Fatigue in Patients With Inflammatory Bowel Disease: A Multicenter Study
17. Tu1335 European Registry on H. pylori Management (HP-EuReg) in Spain: Interim Analysis in First and Second Line Therapies
18. Su1172 Non-Bismuth Quadruple (Concomitant) Therapy for Eradication of H. pylori: Standard vs. Optimized (14-Day, High-Dose PPI) Regimen
19. Su1170 Second-Line Rescue Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection: Time Trends in a Spanish Multicenter Study of 1,400 Patients
20. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn's disease
21. Su1170 Second-Line Rescue Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection: Time Trends in a Spanish Multicenter Study of 1,400 Patients
22. Tu1335 European Registry on H. pylori Management (HP-EuReg) in Spain: Interim Analysis in First and Second Line Therapies
23. Tu1107 Adalimumab Dose Escalation Is Effective for Managing Loss of Response in Ulcerative Colitis
24. Su1132 Helicobacter pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy
25. 538 Correlation Between Adalimumab Serum Levels and Remission After the Induction Phase in Crohn's Disease Patients
26. Su1129 H. pylori Second-Line Rescue Therapy With Levofloxacin and Bismuth After Failure of Standard Triple or Non-Bismuth Quadruple Treatment
27. Su1329 Evolution After Anti-TNF Drug Discontinuation in Patients With Inflammatory Bowel Disease (IBD): A Multicenter Long-Term Follow-Up Study
28. Sa1917 Third-Line Rescue Therapy With Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (With Clarithromycin and Levofloxacin) to Eradicate Helicobacter pylori Infection
29. Genetics of inflammatory bowel disease: population aspects
30. Sa1917 Third-Line Rescue Therapy With Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (With Clarithromycin and Levofloxacin) to Eradicate Helicobacter pylori Infection
31. Su1957 - Serial Tuberculin Skin Test Improves the Detection of Latent Tuberculosis Infection in Inflammatory Bowel Disease Patients
32. Su1329 Evolution After Anti-TNF Drug Discontinuation in Patients With Inflammatory Bowel Disease (IBD): A Multicenter Long-Term Follow-Up Study
33. Tu1107 Adalimumab Dose Escalation Is Effective for Managing Loss of Response in Ulcerative Colitis
34. 538 Correlation Between Adalimumab Serum Levels and Remission After the Induction Phase in Crohn's Disease Patients
35. Su1132 Helicobacter pylori First-Line and Rescue Treatments in the Presence of Penicillin Allergy
36. Su1683 Third-Line Rescue Therapy With Levofloxacin After Failure of Two Treatments to Eradicate Helicobacter pylori Infection
37. Su1681 Second-Line Rescue Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection: Time Trends in a Spanish Multicenter Study of 1,000 Patients
38. Second-Line Rescue Therapy With Levofloxacin After H. pylori Treatment Failure. Time Trends of Eradication in a Spanish Multicenter Study of 830 Patients
39. Prospective Controlled Analysis of Vitamin B12 and Folate Deficiency in Crohn's Disease
40. Cancer characteristics in Swedish families fulfilling criteria for hereditary nonpolyposis colorectal cancer
41. W1197 Effectiveness and Adverse Effects of Azathioprine in Inflammatory Bowel Disease: 5-Year Follow-up Study
42. M1114 Second-Line Rescue Therapy With Levofloxacin After H. pylori Treatment Failure. A Spanish Multicenter Study of 657 Patients
43. Su1683 Third-Line Rescue Therapy With Levofloxacin After Failure of Two Treatments to Eradicate Helicobacter pylori Infection
44. Su1681 Second-Line Rescue Therapy With Levofloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection: Time Trends in a Spanish Multicenter Study of 1,000 Patients
45. Second-Line Rescue Therapy With Levofloxacin After H. pylori Treatment Failure. Time Trends of Eradication in a Spanish Multicenter Study of 830 Patients
46. Prospective Controlled Analysis of Vitamin B12 and Folate Deficiency in Crohn's Disease
47. Tu1175 Incidence and Characteristics of Intestinal and Extraintestinal Cancers in Patients With Inflammatory Bowel Disease: A Population-Based Study
48. Su1164 Second-Line Rescue Therapy With Moxifloxacin After Failure of Treatment to Eradicate Helicobacter pylori Infection
49. 210 Management and Course of Inflammatory Bowel Disease Patients With Associated Cancer
50. Tu1704 Effect of Chondroitin Sulphate on Pro-Inflammatory Mediators and Disease Activity in Patients With Inflammatory Bowel Disease (IBD)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.